Drug Trial Radar · NCT04801056
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
Last checked: Nov 19, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 1, 2021
Primary completion
Sep 1, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- TrueBinding, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients. The primary objective of TB006 treatment is to decrease the potential acute severe deterioration in outpatient COVID-19 patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are considered at low risk for severe disease or hospitalization.
Conditions
- Covid19
Interventions
TB006Drug
TB006 monoclonal antibody
PlaceboOther
Placebo i.v. infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse eventsTime frame: Baseline to Day 85
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.